IDH野生型胶质母细胞瘤的长期生存:ETERNITY脑肿瘤资助者协作联盟(EORTC 1419)首次结果
ETERNITY注册研究在欧美澳24个中心识别诊断后生存至少5年的胶质母细胞瘤患者,分析189例IDH野生型患者预后因素。中位总生存9.9年(95%CI 7.9-11.9),无复发患者中位生存未达到,优于有复发患者的8.92年(p<0.001),且MGMT启动子未甲基化比例达48.8%。
要点
- IDH野生型长期生存者中位总生存9.9年(95%CI 7.9-11.9)。
- 无复发患者中位生存未达到,优于有复发患者的8.92年(p<0.001)。
- 无复发患者中MGMT启动子未甲基化肿瘤比例达48.8%。
核心结论
- 无进展生存是胶质母细胞瘤长期生存者总生存的强预测因素。
- 无复发患者常为MGMT启动子未甲基化胶质母细胞瘤,可能代表一种独特的胶质母细胞瘤亚型。
研究设计与样本
- EORTC 1419(ETERNITY)是由美国脑肿瘤资助者协作联盟和EORTC脑肿瘤组支持的注册研究。
- 在欧洲、美国和澳大利亚的24个中心识别诊断后生存至少5年的胶质母细胞瘤患者。
- 在IDH野生型肿瘤患者中,采用Kaplan-Meier法和Cox比例风险模型分析预后因素。
- 从苏黎世州癌症注册处获取基于人群的参考队列。
- 截至2020年7月数据库锁定,共注册280例经中心病理确诊的胶质母细胞瘤患者(189例IDH野生型,80例IDH突变型,11例特征不完全)。
主要发现
- IDH野生型人群中,中位年龄56岁(范围24-78岁),96例(50.8%)为女性,139例(74.3%)肿瘤具有MGMT启动子甲基化。
- 中位总生存为9.9年(95%CI 7.9-11.9)。
- 无复发患者中位生存未达到,有1次或以上复发患者为8.92年(p<0.001)。
- 无复发患者中MGMT启动子未甲基化肿瘤比例高达48.8%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with long-term survival remain poorly defined. METHODS: European Organization for Research and Treatment of Cancer (EORTC) 1419 (ETERNITY) is a registry study supported by the Brain Tumor Funders Collaborative in the US and the EORTC Brain Tumor Group. Patients with glioblastoma surviving at least 5 years from diagnosis were identified at 24 sites in Europe, US, and Australia. In patients with isocitrate dehydrogenase (IDH) wildtype tumours, prognostic factors were analysed using the Kaplan-Meier method and the Cox proportional hazards model. A population-based reference cohort was obtained from the Cantonal cancer registry Zurich. RESULTS: At the database lock of July 2020, 280 patients with histologically centrally confirmed glioblastoma (189 IDH wildtype, 80 IDH mutant, 11 incompletely characterised) had been registered. In the IDH wildtype population, median age was 56 years (range 24-78 years), 96 patients (50.8%) were female, 139 patients (74.3%) had tumours with O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Median overall survival was 9.9 years (95% confidence interval [95% CI] 7.9-11.9). Patients without recurrence experienced longer median survival (not reached) than patients with one or more recurrences (8.92 years) (p < 0.001) and had a high rate (48.8%) of MGMT promoter-unmethylated tumours. CONCLUSIONS: Freedom from progression is a powerful predictor of overall survival in long-term survivors with glioblastoma. Patients without relapse often have MGMT promoter-unmethylated glioblastoma and may represent a distinct subtype of glioblastoma.
引用
- Hertler C, Felsberg J, Gramatzki D, et al. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419). Eur J Cancer. 2023. PMID: 37277265. doi:10.1016/j.ejca.2023.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。